Hong Kong Wireless Telecom Stock News

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has quietly been on a strong run this year, with the stock up around 175% year to date and roughly 150% over the past year. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. That kind of year to date share price return, combined with a 1 year total shareholder return of roughly 150 percent, signals that sentiment has swung sharply toward Kelun Biotech as investors price in faster growth and a lower perceived risk...

MMG Limited recently reshaped its leadership structure, appointing Cao Liang as Chairman, expanding executive roles including a new COO, and formalising a refreshed board and committee line-up to align with updated corporate governance requirements. The creation of a Lead Independent Non-Executive Director role and elevation of regional presidents to the Executive Committee point to a stronger focus on board oversight and operational accountability across key assets such as Las Bambas and...

As global markets keenly await the final Federal Reserve meeting of the year, Asian markets are navigating a landscape marked by mixed economic signals and cautious optimism. Amid these conditions, penny stocks—often smaller or newer companies with potential for significant growth—continue to capture investor interest due to their affordability and growth prospects. While the term 'penny stocks' might seem outdated, these investments can still represent valuable opportunities when backed by...

Weimob (SEHK:2013) just saw its chairman and CEO, Sun Taoyong, scoop up another 1,534,000 shares. This move puts real money behind the company’s AI focused strategy and recent incentive plans. See our latest analysis for Weimob. That confidence comes after a tough stretch, with Weimob’s share price down 40.18 percent year to date and a 90 day share price return of minus 17.84 percent, even as the 1 year total shareholder return is a positive 21.47 percent. This suggests recent insider buying...

Country Garden Holdings (SEHK:2007) just cleared a major hurdle in its turnaround, with a court sanctioned offshore debt restructuring scheme and bondholder approved changes to several onshore bonds reshaping its capital structure. See our latest analysis for Country Garden Holdings. Investors have welcomed this progress, with a recent 1 day share price return of 1.96 percent suggesting sentiment is improving. However, a deeply negative 3 year total shareholder return of 83.01 percent shows...

People's Insurance Company Group of China SEHK:1339 is back in the spotlight after its PICC Property and Casualty unit addressed market rumors about senior executives, stating that operations remain normal despite the recent rumor driven share price swings. See our latest analysis for People's Insurance Company (Group) of China. The clarification from PICC P&C comes after a rumor driven spike in volatility, with the share price now at HK$7.01. This builds on a strong year to date 90.49...

Shanghai Junshi Biosciences (SEHK:1877) has quietly pulled back after a strong year to date, and that dip is starting to catch investors’ attention as they reassess the biotech’s growth profile and risks. See our latest analysis for Shanghai Junshi Biosciences. Despite the recent pullback, Shanghai Junshi Biosciences is still sitting on a strong year to date share price return. This suggests that earlier optimism about its drug pipeline and earnings trajectory is now cooling as investors...

Greentown China Holdings (SEHK:3900) just released unaudited operating data for the eleven months to November 2025, showing sizeable contracted sales and healthy sales area across both self investment and project management projects. See our latest analysis for Greentown China Holdings. The latest operating update seems to be nudging sentiment in the right direction, with a roughly 10 percent 1 month share price return contrasting with a still negative 1 year total shareholder return. This...

A deadly fire that tore through seven high rise towers in Hong Kong has put China Taiping Insurance Holdings (SEHK:966) under a harsh spotlight, as its local affiliate faces over $200 million in claims. See our latest analysis for China Taiping Insurance Holdings. Despite the tragic fire highlighting near term earnings risk, investors have largely looked through the shock. The share price is up 7.1 percent over one day and has delivered a powerful 67.4 percent year to date share price return,...

Jiangsu Expressway Company Limited has announced plans, ahead of its 18 December 2025 EGM, to abolish its Supervisory Committee and amend its Articles of Association, marking a significant shift in its corporate governance structure. This move is drawing attention because reconfiguring oversight mechanisms can alter how investors assess accountability, control, and long‑term governance quality at the company. We will now examine how the proposed abolition of the Supervisory Committee could...

Recent coverage highlighted that Dongfeng Motor Group continues to own 100% of Hong Kong-based EV subsidiary VOYAH, as investors revisit its potential spin-off amid active spin-off interest in the Hong Kong market. The discussion of VOYAH’s standalone valuation, competitive position in China’s crowded EV sector, and Hong Kong listing rules offers fresh insight into how a spin-off could reshape Dongfeng’s business profile. We will now examine how the renewed focus on a possible VOYAH spin-off...

United Laboratories International Holdings recently reported that its wholly owned Zhongshan branch of Zhuhai United Laboratories received China National Medical Products Administration approval, with quality and efficacy consistency evaluation, for its 2.0g Cefoperazone Sodium and Sulbactam Sodium for Injection, already classified as a Category B drug in the 2024 National Medical Insurance Drug List. This outcome strengthens the company’s anti-infective portfolio by validating a...

GoFintech Quantum Innovation (SEHK:290) just flipped its half year results from a small loss to a net profit, and that earnings swing is quickly becoming the main story behind the stock’s recent momentum. See our latest analysis for GoFintech Quantum Innovation. That earnings swing helps explain why the share price has climbed to HK$2.29, with a powerful year to date share price return of 186.25% and a remarkable three year total shareholder return of 1,599.01%, suggesting momentum is still...

Xiaomi (SEHK:1810) just posted a standout third quarter, with several metrics hitting record highs and its Cars unit delivering a breakthrough as smart electric vehicle and innovation revenue surged more than 199% year over year. See our latest analysis for Xiaomi. The upbeat quarter has helped Xiaomi regain some investor confidence, with the latest HK$42.78 share price sitting against a solid year to date share price return. A powerful three year total shareholder return above 270% suggests...

New World Development (SEHK:17) has just wrapped up a major debt exchange, issuing about USD 1.36 billion in new bonds and cutting its debt load by nearly 50%, a meaningful shift for equity holders. See our latest analysis for New World Development. The sizeable debt cut seems to have given sentiment a lift, with a 1 day share price return of 4.87% helping extend its year to date share price return of 41.07%. However, the 3 year total shareholder return is still deeply negative at 62.10%. If...

Lygend Resources & Technology (SEHK:2245) has called an Extraordinary General Meeting for December 19, 2025, to seek approval for related party transactions, a move that puts governance and transparency squarely in focus for shareholders. See our latest analysis for Lygend Resources & Technology. The governance spotlight from this Extraordinary General Meeting comes after a sharp run up, with the 188.52% year to date share price return and 147.95% one year total shareholder return suggesting...

CSPC Pharmaceutical Group (SEHK:1093) just cleared two regulatory hurdles, securing trial approvals in China and the US for first in class obesity and kidney disease candidates, giving investors fresh, data-driven reasons to revisit the stock. See our latest analysis for CSPC Pharmaceutical Group. These back to back trial greenlights land at a time when CSPC Pharmaceutical Group’s 1 year total shareholder return of 58.59 percent contrasts sharply with a weak 90 day share price return of...

HSBC Global Research has just spotlighted Harbin Electric (SEHK:1133), highlighting its role in nuclear and hydropower supply as China wrestles with energy oversupply and fast rising demand from AI driven data centers. See our latest analysis for Harbin Electric. The HSBC call lands on a stock that has already been on a tear, with a roughly 66% 3 month share price return and a near fivefold 1 year total shareholder return, suggesting momentum is still very much intact despite only modest...

Onewo (SEHK:2602) just put a clear marker down by kicking off a buyback of up to 10% of its H shares, signaling confidence in its long term outlook and capital discipline. See our latest analysis for Onewo. The buyback news lands after a choppy stretch, with a 30 day share price return of minus 11.07% and a three year total shareholder return of minus 55.31%. Management is clearly trying to reset sentiment and rebuild momentum. If this kind of opportunistic capital return has you thinking...

Ascentage Pharma Group International (SEHK:6855) has quietly outperformed over the past year, and with shares up roughly 56% in that time, investors are starting to revisit the story behind this clinical stage biotech. See our latest analysis for Ascentage Pharma Group International. The stock has been choppy in recent months, with a 1 day share price return of 4.44 percent and a 90 day share price return of minus 19.91 percent. However, a 1 year total shareholder return of 55.76 percent...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

In late November 2025, Ascletis Pharma announced it had selected ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist developed with its POTENT and AI-assisted technologies, as a clinical development candidate and outlined plans to file a US FDA Investigational New Drug application for obesity treatment in 2026. The company highlighted that ASC37 showed much higher in vitro potency and substantially improved oral bioavailability versus existing incretin drugs in non-human primate studies,...

Earlier this month, a coalition of major Chinese state-owned enterprises and academic institutions, including China Petroleum & Chemical Corp. (Sinopec), launched an initiative to promote dimethyl ether (DME) as a cleaner and safer next-generation marine fuel, targeting advances in production, engine systems, refueling infrastructure, and safety standards. This alliance positions Sinopec at the center of efforts to accelerate low-emission shipping fuels, potentially reinforcing its role in...

There wouldn't be many who think Swire Pacific Limited's ( HKG:19 ) price-to-sales (or "P/S") ratio of 1x is worth a...